Ideaya Biosciences is trading 4.18% down at $36.47, with biotech-sector weakness the clearest available explanation.
- Biotech stocks are broadly lower, with XBI down 2.50%.
- No company-specific announcement explaining the October 6 move surfaced in the available search.
- Cantor Fitzgerald reiterated its Overweight rating, but the report did not link it to the decline. Major indexes are higher.